CA
NZ
UK
AU
IND
US
● AbbVie's lutikizumab showed only a modest benefit in hidradenitis suppurativa.
● The FDA accepted the resubmission as a complete response to its November 4, 2025 letter.
● The stock reached about $0.77 after hours, which is not a closing price.
● Adjusted earnings of $0.36 a share beat the $0.24 forecast.
● KRRO-111 achieved high levels of editing of SERPINA1 messenger RNA in preclinical studies.
● The micro-cap biotech has a market value of roughly $50 million.
● AbbVie's lutikizumab showed only a modest benefit over placebo.
● The figure is a snapshot rather than a closing price.
● The figure is an intraday snapshot rather than a confirmed close.
● The company has a market value of about $21.5 million.
Please wait processing your request...